SG11201806274SA - Copanlisib biomarkers - Google Patents

Copanlisib biomarkers

Info

Publication number
SG11201806274SA
SG11201806274SA SG11201806274SA SG11201806274SA SG11201806274SA SG 11201806274S A SG11201806274S A SG 11201806274SA SG 11201806274S A SG11201806274S A SG 11201806274SA SG 11201806274S A SG11201806274S A SG 11201806274SA SG 11201806274S A SG11201806274S A SG 11201806274SA
Authority
SG
Singapore
Prior art keywords
international
biomarkers
pct
copanlisib
english
Prior art date
Application number
SG11201806274SA
Inventor
Li Liu
Carol Pena
Jie Cheng
Karl Köchert
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201806274SA publication Critical patent/SG11201806274SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1101111 0 HEIN HO 11111 0 111 01111 1110 11101110110 111E1111 MI International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/134000 Al 10 August 2017(10.08.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) A61K 31/519 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/EP2017/051903 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 30 January 2017 (30.01.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/289,713 1 February 2016 (01.02.2016) US 62/376,017 17 August 2016 (17.08.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: BAYER PHARMA AKTIENGESELL- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, SCHAFT [DE/DE]; MfillerstraBe 178, 13353 Berlin (DE). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: LIU, Li; 11 Hillside Drive, NJ, East Hanover TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 07936 (US). PENA, Carol; 341 Mount Airy Rd, NJ, Bask- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, ing Ridge 07920 (US). CHENG, Jie; 18 Dixon Ln, Belle Mead, NJ 08502 (US). KOCHERT, Karl; Kirschallee SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 174, 14469 Potsdam (DE). GW, KM, ML, MR, NE, SN, TD, TG). Published: (74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Monheim am Rhein NRW (DE). — with international search report (Art. 21(3)) 1-1 © © © 7r M Il (54) Title: COPANLISIB BIOMARKERS 1-1 C (57) : This invention provides biomarkers based on the gene expression profiling which can discriminate between patients N who response to and/or with longer progression free survival and patients who do not response to and/or with shorter progression 0 free survival from copanlisib treatment in lymphoma including indolent and aggressive NHLs and CLLs. The present invention relates to the use of genes from the BCR, PI3K, NFkB, 1L6, inflammation and stromal processes as predictive biomarkers for various human cancers including but not limited to NHLs.
SG11201806274SA 2016-02-01 2017-01-30 Copanlisib biomarkers SG11201806274SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662289713P 2016-02-01 2016-02-01
US201662376017P 2016-08-17 2016-08-17
PCT/EP2017/051903 WO2017134000A1 (en) 2016-02-01 2017-01-30 Copanlisib biomarkers

Publications (1)

Publication Number Publication Date
SG11201806274SA true SG11201806274SA (en) 2018-08-30

Family

ID=57984901

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007262PA SG10202007262PA (en) 2016-02-01 2017-01-30 Copanlisib biomarkers
SG11201806274SA SG11201806274SA (en) 2016-02-01 2017-01-30 Copanlisib biomarkers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202007262PA SG10202007262PA (en) 2016-02-01 2017-01-30 Copanlisib biomarkers

Country Status (16)

Country Link
US (1) US20190038632A1 (en)
EP (1) EP3411497A1 (en)
JP (1) JP2019511204A (en)
KR (1) KR20180101603A (en)
CN (1) CN108884496A (en)
AU (1) AU2017214230A1 (en)
BR (1) BR112018015782A2 (en)
CA (1) CA3012890A1 (en)
CL (1) CL2018002069A1 (en)
MA (1) MA43957A (en)
MX (1) MX2018009368A (en)
PH (1) PH12018501623A1 (en)
SG (2) SG10202007262PA (en)
SV (1) SV2018005730A (en)
TN (1) TN2018000271A1 (en)
WO (1) WO2017134000A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
MX2017011635A (en) 2015-03-09 2018-02-09 Bayer Pharma AG Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations.
CN108884098B (en) 2016-03-08 2021-09-14 拜耳制药股份公司 2-amino-N- [ 7-methoxy-2, 3-dihydroimidazo [1,2-c ] quinazolin-5-yl ] pyrimidine-5-carboxamides
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
CN109729716B (en) 2016-09-23 2022-03-15 拜耳制药股份公司 PI3K inhibitor combination
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
MX2020002633A (en) * 2017-09-08 2020-07-13 Bayer Consumer Care Ag Formulations of copanlisib.
WO2020092860A1 (en) * 2018-11-01 2020-05-07 The Jackson Laboratory Gastric cancer treatments
EP4231872A1 (en) 2020-10-21 2023-08-30 Black Jet Innovations, Inc. Mobile device grip and stand

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2908776C (en) * 2013-04-08 2021-08-10 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
DK3543355T3 (en) * 2013-06-20 2021-03-01 Taiho Pharmaceutical Co Ltd PROCEDURE FOR PREDICTING THERAPEUTIC EFFECTIVENESS OF PI3K / AKT / MTOR INHIBITORS BASED ON PHLDA1 OR PIK3C2B EXPRESSION
AU2015230677A1 (en) * 2014-03-11 2016-10-27 The Council Of The Queensland Institute Of Medical Research Determining cancer agressiveness, prognosis and responsiveness to treatment
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
CN105130998B (en) * 2015-09-25 2017-07-28 苏州立新制药有限公司 Ku Pannixi preparation method
CN105130997B (en) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 A kind of Ku Pannixi preparation method

Also Published As

Publication number Publication date
US20190038632A1 (en) 2019-02-07
MX2018009368A (en) 2018-09-05
EP3411497A1 (en) 2018-12-12
CL2018002069A1 (en) 2018-11-16
SG10202007262PA (en) 2020-09-29
PH12018501623A1 (en) 2019-06-03
JP2019511204A (en) 2019-04-25
SV2018005730A (en) 2018-12-05
TN2018000271A1 (en) 2020-01-16
WO2017134000A1 (en) 2017-08-10
BR112018015782A2 (en) 2019-01-02
AU2017214230A1 (en) 2018-08-09
CA3012890A1 (en) 2017-08-10
KR20180101603A (en) 2018-09-12
CN108884496A (en) 2018-11-23
MA43957A (en) 2018-12-12

Similar Documents

Publication Publication Date Title
SG11201806274SA (en) Copanlisib biomarkers
SG11201806512VA (en) Copanlisib biomarkers
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804934PA (en) Novel Compounds
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201806261XA (en) Bcma antibodies and use of same to treat cancer and immunological disorders
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201810018TA (en) Phosphoramidate nucleoside derivatives as anticancer agents
SG11201804916PA (en) Three-dimensional polymer networks with channels situated therein
SG11201808539WA (en) Mouth piece for cooling of oral tissue of a patient during chemotherapy treatment
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201809341PA (en) Mobile robot
SG11201805184TA (en) Combination therapy
SG11201810196RA (en) Cancer treatments
SG11201804889XA (en) Fluid interface device for delivering fluid to and/or withdrawing fluid from a patient